KRAS and colorectal carcinoma: Although studies have shown that KRAS mutation status is unrelated to the effect of anti-PD-1 therapy (Overman et al., 2018), Liao W et al. found that KRAS mutation status in MSS CRC might still be mediated through IRF2 suppression.